Skip to main content
. 2016 Nov 3;17:530. doi: 10.1186/s13063-016-1656-y

Table 1.

Eligibility criteria

Inclusion criteria
Subjects > 70 years of age
Either gender
First diagnosis of heart failure defined as:
 a) Mild or moderate symptomatic heart failure (NYHA calss I to III)
 b) An echocardiographic left ventricular ejection fraction ≥ 40%
Patients who provide written informed consent
Exclusion criteria
History and/or clinical documentation of pulmonary embolism
Severe heart failure (NYHA IV or need for inotropic support)
Primary valvular heart disease
Pericardial disease
Severe obstructive lung disease
Primary pulmonary hypertension
Occupational lung disease
Asthma
Severe renal failure (serum creatinine >2.0 mg/dL)
Significant peripheral vascular disease
Severe bradycardia (heart rate< 50 beats/minutes)
Second or third-degree atrio-ventricular block
Atrial fibrillation
Life expectancy < 1 year
Concern for inability of the patient to comply with study procedures and/or follow up
Any condition which in the opinion of the Investigator would make it unsafe or unsuitable for the patient to participate in this study
Involvement in the planning and/or conduct of the study
Participation in another clinical study with an investigational product during the preceding 30 days
Unable to give informed consent